Summit Therapeutics shares rise 9.22% intraday after Harmoni-A trial shows ivonescimab plus chemo delivers statistically significant survival benefit in EGFRm NSCLC.

Summit Therapeutics surged 9.22% intraday following updated phase III HARMONi trial data showing ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit (hazard ratio of 0.78, nominal p=0.0332) in second-line EGFR-mutated non-small cell lung cancer. The results, disclosed in early September 2025, strengthened the case for the drug’s Biologics License Application (BLA) submission to the FDA by year-end, despite prior setbacks in meeting overall survival requirements. The positive data, combined with recent analyst upgrades (e.g., Cantor Fitzgerald’s "overweight" rating) and insider share purchases, fueled optimism about regulatory and commercial prospects, directly driving the intraday rally.